GSK publish series of p38 MAP kinase inhibitors

GSK publish series of Pyrazolo[1,5-a]pyridine p38 MAP kinase inhibitors

Cyclacel refocuses on non kinase projects

Cyclacel to focus resources on the advancement of its lead drug, sapacitabine. Workforce to be reduced by 28 employees (34% of total staff); Cambridge facility to be closed
It has not yet been decided if the company will further development CDK inhibitor Seliciclib or Aurora kinase inhibitor CYC116

Telik publish series of insulin receptor (IR) tyrosine kinase inhibitors

Telik have published a series of insulin receptor tyrosine kinase (IRTK) inhibitors.

Dasatinib effective in imatinib-resistant PDGFRA D842V mutant isoform

In vitro data suggests that Dasatinib may be effective against imatinib-resistant GIST PDGFRA D842V mutant isoforms

Pfizer ATM inhibitor CP466722 effective in sensitizing cells to irradiation

Treatment of cells with Pfizer’s ATM inhibitor CP466722 sensitized them to irradiation

Avastin demonstrates overall survival in metastatic colorectal cancer patients with K-Ras gene status

Data presented at the European of Medical Oncology (ESMO) show Avastin (bevacizumab) is the only biologic to provide overall survival (OS) benefit when used as first-line treatment in combination with chemotherapy for patients with K-Ras wild type metastatic colorectal cancer (mCRC).

Pazopanib demonstrates efficacy in Sarcoma and Ovarian cancer

Phase III data presented at the European of Medical Oncology (ESMO) show pazopanib to be effective in soft tissue sarcoma (STS), epithelial ovarian cancer, and non small cell lung cancer. GSK plan to initiate Phase III trials in other cancer types.

GSKs Tykerb (lapatinib) effective in advanced head and neck cancer

Phase II data presented at the European of Medical Oncology (ESMO) show that GSK’s Tykerb (lapatinib) is effective in advanced head and neck cancer

Pfizers IGF-1R MAb CP-751,871 effective in NSCLC

Phase II data presented at the European of Medical Oncology (ESMO) show that Pfizer’s IGF-1R inhibitor CP-751,871 shows efficacy in patients with non-small cell lung cancer (NSCLC).

Erbitux continues to be effective in metastatic colorectal cancer

Data presented at the European of Medical Oncology (ESMO) show that Erbitux, plus FOLFIRI, continueds to show efficacy in patients with previously untreated metastatic colorectal cancer (mCRC).